focus -WSS

focus

author：comprehensive 2025-09-27 09:59:11 - browse：3563

CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers applying for approval with data from trials solely run in a single country such as China, but instead wants to see companies conducting studies across the world.

The comments by Richard Pazdur, director of the FDA’s Oncology Center of Excellence, came as more drugmakers report data from China, with Miami-based Summit Therapeutics earlier this week announcing that its investigational drug beat Merck’s blockbuster Keytruda in a head-to-head non-small cell lung cancer study in China.

It’s not a blanket policy, and the agency would assess each company’s submission to see how applicable the data are to the U.S. population, but in general, “I am pro multi-regional trials,” Pazdur said Friday at STAT@ASCO, STAT’s event at the American Society of Clinical Oncology annual meeting.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： Biden tests positive for Covid

WSS

The Readout: Lenmeldy, GLP

FDA's naming rule on biosimilars has undermined competition

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Washington mulls new rules to avert another Change Healthcare

Abortion pill Supreme Court ruling could impact entire drug industry

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

At Orexo, a ‘turning point’ for everything but digital health

In Memoriam: Notable people who died in 2023

A public scorecard can help hold safety

Medicare proposal to cover medical devices draws a mixed reaction

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

The high cost of giving birth even with insurance

Group opposing PBM reform sets lobbying record

Trump demands the U.S. pay no more for drugs than other countries … again

Food as medicine: Medically tailored meals may get standardized

hotspot

Eliminate the waiting period for sterilization covered by Medicaid

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

Sanders adds drug shortage policies to pandemic preparedness bill

States should stop sabotaging methadone treatment reform

The Readout: Lenmeldy, GLP

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

knowledge

entertainment

leisure time

Wikipedia